Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sai Gutti

Interventional Pain Medicine Pikeville, KY Medical Doctor

NPI 1992805410 CMS profile 226142

515 N Bypass Rd, Suite 101, Pikeville, KY 41501

Open in the dashboard

General payments

$9,014

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sai Gutti of Pikeville, KY is reported in the CMS Open Payments database as having received $9,014 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,975 96
2024 General $1,379 70
2023 General $1,707 42
2022 General $2,816 69
2021 General $538 42
2020 General $88 6
2019 General $511 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sai Gutti
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Sai Gutti were reported at $1,975. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Sai Gutti Interventional Pain Medicine median Middle half National median
2019 $511 $684 $216–$2,079 $163
2020 $88 $382 $122–$1,109 $114
2021 $538 $552 $167–$1,554 $132
2022 $2,816 $605 $187–$1,924 $149
2023 $1,707 $671 $195–$1,915 $160
2024 $1,379 $684 $206–$1,837 $164
2025 $1,975 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,192 104 payments
  2. Pacira Pharmaceuticals Incorporated $1,170 8 payments
  3. Biogen, Inc. $997 54 payments
  4. Teva Pharmaceuticals USA, Inc. $326 18 payments
  5. Merck Sharp & Dohme Corporation $314 16 payments
  6. Novartis Pharmaceuticals Corporation $307 16 payments
  7. SK Life Science, Inc. $242 14 payments
  8. Daiichi Sankyo Inc. $188 10 payments
  9. Janssen Biotech, Inc. $159 8 payments
  10. Supernus Pharmaceuticals, Inc. $150 15 payments
  11. Other $1,968 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,566 360 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,641 2 payments
  3. Travel and Lodging $806 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $2,636 61 payments
  2. Iovera $1,170 8 payments
  3. QULIPTA $1,102 69 payments
  4. TYSABRI $827 44 payments
  5. VUMERITY $718 37 payments
  6. KEYTRUDA $250 12 payments
  7. Exparel $194 3 payments
  8. ENHERTU $154 8 payments
  9. AUSTEDO $153 9 payments
  10. KESIMPTA $151 7 payments
  11. Other $3,167 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,459

Median for Interventional Pain Management: 1,220

Drug cost

$42,138

Median for Interventional Pain Management: $39,344

Branded share of claims

33.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 39 $13,890
Fentanyl Generic 76 $7,864
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 140 $3,834
Oxycodone Hcl Generic 168 $2,772
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 221 $2,595
Celecoxib Generic 190 $2,408
Duloxetine Hcl Generic 232 $2,391
Dronabinol Generic 17 $1,890
Morphine Sulfate Er Morphine Sulfate Brand 78 $1,565
Naloxone Hcl Generic 27 $1,294

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$40,995

Medicare's payments for the services billed

Medicare patients

510

Average age 70

Services billed

622

252 women, 258 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 43%
Ischemic heart disease 37%
COPD 37%
Depression 35%
Chronic kidney disease 27%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $166
$166 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $154
$154 — —
VUMERITY
  • Biogen, Inc. $145
$145 — —
QULIPTA
  • AbbVie, Inc. $141
$141 — —
TYSABRI
  • Biogen, Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record